Silexion Therapeutics (SLXN) Net Cash Flow (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Net Cash Flow of -$3.6 million for Q1 2026, down 171.65% year-over-year from $5.0 million in Q1 2025, and down 9.83% quarter-over-quarter from -$3.2 million in Q4 2025.
Silexion Therapeutics (SLXN) Net Cash Flow (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Net Cash Flow history runs 4 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 171.65% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$3.7 million (down 209.13% YoY), while the FY2025 annual figure was $4.8 million, up 245.05% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$3.6 million, down from -$3.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $5.8 million in Q3 2025, with the low at -$3.6 million in Q1 2026.
- The 4-year median for Net Cash Flow is -$1.1 million (2023), against an average of -$425000.0.
- Peak annual rise in Net Cash Flow reached 2203.19% in 2025, while the deepest fall reached 337.2% in 2025.
- Silexion Therapeutics' Net Cash Flow stood at -$1.3 million in 2023, then jumped by 41.16% to -$742000.0 in 2024, then slumped by 337.2% to -$3.2 million in 2025, then retreated by 9.83% to -$3.6 million in 2026.
- Business Quant data shows SLXN's Net Cash Flow at -$3.6 million in Q1 2026, -$3.2 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | -186,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -186,000.00 |
| Jun 30, 2026 | -186,000.00 |
| Mar 31, 2026 | -3.56 Mn |
| Mar 31, 2026 | -3.56 Mn |
| Dec 31, 2025 | -3.24 Mn |
| Dec 31, 2025 | -3.24 Mn |
| Sep 30, 2025 | 5.78 Mn |
| Sep 30, 2025 | 5.78 Mn |
| Jun 30, 2025 | -2.70 Mn |
| Jun 30, 2025 | -2.70 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | -742,000.00 |
| Dec 31, 2024 | -742,000.00 |
| Sep 30, 2024 | 251,000.00 |
| Sep 30, 2024 | 251,000.00 |
| Jun 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Mar 31, 2024 | -1.76 Mn |